166 related articles for article (PubMed ID: 37294909)
21. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
22. Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy.
Oliveira CV; Camozzato TSC; Dorow PF; Pasqueta J
J Nucl Med Technol; 2022 Sep; 50(3):233-239. PubMed ID: 36215644
[TBL] [Abstract][Full Text] [Related]
23. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
[TBL] [Abstract][Full Text] [Related]
24. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
25. Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD's voxel S values in Graves' disease.
Fujita N; Koshiba Y; Abe S; Kato K
EJNMMI Phys; 2020 Jan; 7(1):6. PubMed ID: 31993828
[TBL] [Abstract][Full Text] [Related]
26. Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET/CT imaging of mice.
Gupta A; Lee MS; Kim JH; Park S; Park HS; Kim SE; Lee DS; Lee JS
Phys Med Biol; 2019 Apr; 64(9):095007. PubMed ID: 30913544
[TBL] [Abstract][Full Text] [Related]
27. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Hobbs RF; Jentzen W; Bockisch A; Sgouros G
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
[TBL] [Abstract][Full Text] [Related]
28. Personalized dosimetry of
Carter LM; Ocampo Ramos JC; Kesner AL
Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
[No Abstract] [Full Text] [Related]
29. Comparison of voxel S-value methods for personalized voxel-based dosimetry of
Kim KM; Lee MS; Suh MS; Selvam HSMS; Tan TH; Cheon GJ; Kang KW; Lee JS
Med Phys; 2022 Mar; 49(3):1888-1901. PubMed ID: 35014699
[TBL] [Abstract][Full Text] [Related]
30. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.
Taprogge J; Vergara-Gil A; Leek F; Abreu C; Vávrová L; Carnegie-Peake L; Schumann S; Eberlein U; Lassmann M; Schurrat T; Luster M; Verburg FA; Vallot D; Vija L; Courbon F; Newbold K; Bardiès M; Flux G
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3225-3234. PubMed ID: 37300572
[TBL] [Abstract][Full Text] [Related]
31. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
32. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
Sakulpisuti C; Charoenphun P; Chamroonrat W
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956886
[TBL] [Abstract][Full Text] [Related]
33. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
34. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
36. Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma.
Verburg FA
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):253-257. PubMed ID: 31271272
[TBL] [Abstract][Full Text] [Related]
37. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.
Eberlein U; Scherthan H; Bluemel C; Peper M; Lapa C; Buck AK; Port M; Lassmann M
J Nucl Med; 2016 Feb; 57(2):173-9. PubMed ID: 26564321
[TBL] [Abstract][Full Text] [Related]
38. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.
Besemer AE; Grudzinski JJ; Weichert JP; Hall LT; Bednarz BP
Cancer Biother Radiopharm; 2019 Feb; 34(1):13-23. PubMed ID: 30351218
[TBL] [Abstract][Full Text] [Related]
40. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
Lassmann M; Hänscheid H; Chiesa C; Hindorf C; Flux G; Luster M;
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1405-12. PubMed ID: 18491092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]